Molecular regulation of cholesterol biosynthesis: Implications in carcinogenesis

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 22, Issue 2, 2003, Pages 75-92

  Singh, R P ^a   Kumar, Raj ^b   Kapur, Nidhi ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY ROORKEE   (India)

^b INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

Carcinogenesis; Cholesterol; Prenylation; Ras

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ANTINEOPLASTIC AGENT; BETA TOCOTRIENOL; CANVENTOL; CHOLESTEROL; COMPACTIN; FLUINDOSTATIN; GERANYL ACETATE; GLIOTOXIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; ISOPRENOID; LIMONENE; MANUMYCIN; MEVALONIC ACID; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE; PATULIN; PERILLIC ACID; PERILLYL ALCOHOL; PRENYLAMINE; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; SIMVASTATIN; STEROL; TRANSFERASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CATALYSIS; CATALYST; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; GENE MUTATION; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PRENYLATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN MOTIF; REACTION ANALYSIS; SIGNAL TRANSDUCTION;

ACYL COENZYME A; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CHOLESTEROL; HUMANS; MEVALONIC ACID; PROTO-ONCOGENE PROTEINS C-RAF; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 0038548583     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvPathToxOncol.v22.i2.10     Document Type: Article

References (116)

1. Spady DK. Regulation of cholesterol metabolism in normal and malignantly transformed tissue in vivo. In: Columbano A, Feo F, Pascale R, Pani P, editors. Chemical Carcinogenesis. 2. New York: Plenum, 1991.
2. Rao KN. The significance of the cholesterol biosynthesis pathway in cell growth and carcinogenesis. Anticancer Res 1995; 15:309-314.
3. Coleman PS, Lorenzino LS. The role of the cholesterol synthesis pathway during tumor cell proliferation. In: Estahani M, Sawaney J, editors. New Jersey: Telford Press, 1990.
4. Buchwald H. Cholesterol inhibition, cancer and chemotherapy. Hypothesis. Lancet 1992; 339:1154-1156.
5. Rilling HC. The mechanism of the condensation reactions of cholesterol biosynthesis. Biochem Soc Trans 1985; 13:997-1003.
6. Edwards PA, Ashby M, Spear DH, Marrero PF, Joly A, Popjak G. Isoprenoid biosynthesis and role in the regulation of protein function. Biochem Soc Trans 1992; 20:475-480.
7. Chen A, Kroon PA, Poulter CD. Isoprenyldiphosphate synthase: protein sequence comparisons, a phylogenetic tree, and predictions of secondary structure. Protein Sci 1994; 3:600-607.
8. Jackson SM, Ericsson J, Edwards PA. Signaling molecules derived from the cholesterol biosynthetic pathway? In: Bittman R, editor. Subcellular Biochemistry. 28 vol. New York: Plenum, 1997.
9. Brown MS, Goldstein JL. Multivalent feedback regulation of HMG-CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 1980; 21:505-517.
10. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343:425-430.
11. Faust JR, Goldstein JL, Brown MS. Squalene synthetase activity in human fibroblasts: regulation via the LDL receptor. Proc Natl Sci USA 1979; 76:5018-5022.
12. Robinson GW, Tsay YH, Bernovdette KK, Constance ASM, Bishop RW. Conservation between human and fungal squalene synthetases: similarities in structure, function, and regulation. Mol Cell Biol 1993; 13(5):2706-2717.
13. Mortensen PB, Kristensen SD, Bloch A, Jacobsen BA, Rasmussen SN. Diagnostic value of ascitic fluid cholesterol levels in the prediction of malignancy. Scand J Gastroenterol 1988; 23:1085-1088.
14. Siperstein MD. Cholesterol, cholesterogenesis and cancer. Adv Exper Med Biol 1995; 369:155.
15. Coleman PS, Lorenzino LS. The role of the cholesterol synthesis pathway during tumor cell proliferation. In: Columbano A, Feo F, Pascale R, Pani P, editors. Chemical Carcinogenesis 2. New York: Plenum, 1991.
16. Rudney H, Sexton RC. Regulation of cholesterol biosynthesis. Annu Rev Nature 1986; 6:245-272.
17. Luskey KL. Regulation of cholesterol synthesis: mechanism for control of HMG-CoA reductase. Rec Prog Horm Res 1988; 44:35-47.
18. Edwards PA, Lan SF, Fegelman AM. Alteration in rates of synthesis and degradation of rat liver 3-hydroxy-3 methylglutaryl coenzyme A reductase produced by cholestyramine and mevinolin. J Biol Chem 1983; 258:10219-10222.
19. Liscum L, Finer MJ, Stroud RM, Luskey KL, Brown KL, Goldstein JL. Domain structure of 3-hydroxy-3-methyl-3-methylylutenyl coenzyme A reductase, a glycoprotein of the endoplasmic reticulum. J Biol Chem 1985; 260:522-530.
20. Keller GA, Pazirandeh M, Krisans S. 3-hydroxy-3-methylglutaryl coenzyme A reductase localization in rat liver peroxisomes and microsomes of control and cholestyramine-treated animals: quantitative biochemical and immoelectron microscopical analyses. J Cell Biol 1986; 103:875-886.
21. Goldstein JL, Brown BMS. Progress in understanding the LDL receptor and HMG-COA reductase, two membrane proteins that regulate the plasma cholesterol. J Lipid Res 1984; 25:1450-1461.
22. Walter P, Blobel G. Signal recognition particle contains 7S RNA essential for protein translocation across the endoplasmic reticulum. Nature 1982; 299:691-698.
23. Reynolds GA, Basu SK, Osborne TF, Chin DJ, Gill G, Brown MS, Goldstein JL, Luskey KL. HMG Co A reductase: a negatively regulated gene with unusual promoter and 5′ untranslated regions. Cell 1984; 38:275-286.
24. Chin DJ, Gill G, Russell DW, Liscum L, Luskey KL, Basu SK, Okayama H, Berg P, Goldstein JL, Brown MS. Nucleotide sequence of HMG CoA reductase, a glycoprotein of the endoplasmic reticulum. Nature 1984; 308:613-617.
25. Fromm M, Berg P. Deletion mapping of DNA regions required for SV40 early region promotor function in vivo. J Mol Appl Genet 1982; 1:457-481.
26. Alberts AW, Chen J, Kuron G, Hunt V, Hutt J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Pathchett A, Monachan R, Currie S, Stapley E, Alberts SG, Hensens O, Hirsfield J, Hoogsteen K, Liesch J, Springer J. A highly potent competitive inhibitor of hydroxy methylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 1980; 77:3957-3961.
27. Gil G, Faust JR, Chin DJ, Goldstein JL, Brown MS. Membrane-bound domain of HMG CoA reductase function is required for stereo-enhanced degradation of the enzyme. Cell 1985; 41:249-258.
28. Nakanishi M, Goldstein JL, Brown MS. Multivalent control of 3-hydroxy-3-methylglutaryl coenzyme A reductase mevalonate-derived product inhibits translocation of mRNA and accelerates degradation of enzyme. J Biol Chem 1988; 263:8929-8937.
29. Correll CC, Ng L, Edwards PA. Identification of farnesol as the non-sterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Biol Chem 1994; 269:17390-17393.
30. Roitelman J, Olender EH, Bar Num S, Dunn WAJ, Simoni RD. Immunological evidence for eight spans in the membrane domain of 3-hydroxy-3-methylglutaryl coenzyme A reductase: implications for enzyme degradation in the endoplasmic reticulum. J Cell Biol 1992; 117:959-973.
31. McKenzie TL, Jiang G, Straubhaar JR, Conrad DG, Shechter I. Molecular cloning, expression and characterization of the cDNA for the rat hepatic squalene synthase. J Biol Chem 1992; 267:21368-21374.
32. Fegueur M, Richard L, Charles AD, Karst F. Isolation and primary structure of the ERG-9 gene of S. cerevisiae encoding squalene synthase. Curr Genet 1991; 20:365-372.
33. Guan G, Guojian J, Rebecca LK, Ishaiahu S. Molecular cloning and functional analysis of the promoter of the human squalene synthase gene. J Biol Chem 1995; 270:21958-21965.
34. Herren J, Steinwaerder DS, Schnieders F, Cichon G, Strauss M, Beisiegel U. Nonphysiological over-expression of low density lipoprotein receptors causes pathological intracellular lipid accumulation and the formation of cholesterol and cholesteryl ester crystals in vitro. J Mol Med 1999; 77(10):735-743.
35. Wade DP, Knight BL, Soutar AK. Regulation of low-density lipoproyein receptor mRNA by insulin in human hepatoma Hep G2 cells. Eur J Biochem 1989; 181:727-731.
36. Parini P, Angelin B, Lobie PE, Norstedt G, Rudling M. Growth hormone specifically stimulates the expression of low-density lipoprotein receptors in human hepatoma cells. Endocrinology 1995; 136:3767-3773.
37. Pak YK, Kanuck MP, Berrios D, Briggs MR, Cooper AD, Ellsworth JL. Activation of LDL receptor gene expression in Hep G2 cells by hepatocyte growth factor. J Lipid Res 1996; 37:985-998.
38. Singh RP, Dhawan P, Golden C, Kapoor GS, Mehta KD. Inhibitor of p38 MAPK isoform in-duces low-density lipoprotein receptor expression through activation of p42/44 MAPK cascade. J Biol Chem 1993; 274:19593-19600.
39. Francke U, Brown MS, Goldstein JL. Assignment of the human gene for the low density lipoprotein receptor to chromosome 19. Synteny of a receptor, a ligand, and a genetic disease. Proc Natl Acad Sci USA 1984; 81:2826-2830.
40. Olaisen B, Teisberg P, Gedde-Dahl T Jr. The locus for apoliporotein E (apoE) is linked to the complement component C3 (C3) locus on chromosome 19 in man. Hum Genet 1982; 62:233-236.
41. Mahley RW, Innerarity TL. Lipoprotein receptors and cholesterol homeostasis. Biochim Biophys Acta 1983; 737:197-222.
42. Rudenko G, Henry L, Henderson K, Jchtchenko K, Brown MS, Goldstein JL. Structure of the LDL receptor extracellular domain at endosomal pH. Science 2002; 298(5602):2337-2339.
43. May P, Reddy YK, Herz J. Proteolytic processing of low density lipoprotein receptor-related protein mediates regulated release of its intracellular domains. J Biol Chem 2002; 277(21):18736-18743.
44. Kovanen PT, Brown MS, Basu SK, Bilheimer DW, Goldstein JL. Saturation and suppression of hepatic lipoprotein receptors a mechanism for the hyper cholesterolemia of cholesterol fed rabbits. Proc Natl Acad Sci USA 1981; 78:1396-1400.
45. Stein CS, Martinis I, Davidson BL. Long-term reversal of hypercholesterolemia in low density lipoprotein receptor (LDLr)-deficient mice by adenovirus mediated LDLr gene transfer combined with CD-154 blockade. J Gene Med 2000; 2(1):41-51.
46. Cherfil J, Chardin P. GEFs: structural basis for their activation of small GTP-binding proteins. Trends Biochem Sci 1999; 24:306-311.
47. Frank MC. Signalling networks that cause cancer. Trends Biochem Sci 1999; 24:53-56.
48. Gibbs JB, Oliff A, Kohl NE. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 1994; 77:175-178.
49. Lacal JC, Tronick SR. The ras oncogene. In: Reddy P, Sakalka AM, Curran T, editors. The Oncogene Handbook. Amsterdam: Elsevier, 1988.
50. Der CJ, Cox AD, Sebti SM, Hamilton AD. Farnesyl-transferase inhibitors: anti Ras drug for cancer treatment? Anticancer Drugs 1996; 7:165-172.
51. Liu HS, Chen CY, Leu CH, Chou YI. Selective activation of oncogenic Ha-Ras-induced apoptosis in NIH3T3 cells. Br J Cancer 1998; 77:1777-1786.
52. Bourne HR, Sanders DA, McCormick F. The GTPase xsuper family: a conserved switch for diverse cell functions. Nature 1990; 348:125-132.
53. Bourne HR, Sanders, DA, McCormick F. The GTPase super family: conserved structure and molecular mechanism. Nature 1990; 349:117-126.
54. Wolfman A, Macara IG. A cytosolic protein catalyzes the release of GDP from P21 ras. Science 1990, 248:67-69.
55. Downward J, Riehl JR, Wu L, Weinberg RA. Identification of nucleotide exchange-promoting activity for p21 ras. Proc Natl Acad Sci USA 1990; 87:5998-6002.
56. Mizuno T, Kaibuchi K, Yamamoto T, Kawamura M, Sakoda T, Fujioka H, Matsuura Y, Takai Y. A stimulatory GDP/GTP exchange protein for smg p21 is active on the post-translationally processed form of C-Ki-ras p21 and rhoA p21. Proc Natl Acad Sci USA 1991; 88:6442-6446.
57. Gilman AG. G-protein and dual control of adenylate cyclase. Cell 1984; 36:577-579.
58. Cox AD, Hisaka MM, Buss JE, Der CJ. Specific isoprenoid modification is required for function of normal but not oncogenic Ras protein. Mol Cell Biol 1992; 12:2606-2615.
59. Magee T, Hanley M. Sticky fingers and CAAX boxes. Nature 1988; 335:114-118.
60. Hancock JF, Cadwallader K, Marshall CJ. Methylation and proteolysis are essential for efficient membrane binding of prenylated p21k-ras(B). EMBO J 1991; 10:641-646.
61. Rebollo A. Novel aspect of Ras protein biology: regulation and implications. Cell Death Differ 1999; 8:722-728.
62. Hall A. The cellular functions of small GTP-binding proteins. Science 1990; 249:635-640.
63. Glomset JA, Farsworth CC. Role of protein modification reactions in programming interactions between Ras-related GTPases and cell membranes. Annu Rev Cell Biol 1994; 10:181-205.
64. Marais R, Marshall CJ. Control of ERK-MAP kinase cascade by Ras and Raf. Cancer Surv 1996; 27:101-125.
65. Van Aelest L, Barr M, Marcus S, Polverino A, Wigler M. Complex formation between Ras and Raf and other protein kinases. Proc Natl Acad Sci USA 1993; 90:6213-6217.
66. Vojteck AB, Hollenberg SM, Cooper JA. Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell 1993; 74:205-214.
67. Koide H, Satoh T, Nakafuku M, Kaziro Y. GTP-dependent association of Raf-1 with Ha-Ras: identification of Raf as a target downstream of Ras in mammalian cells. Proc Natl Acad Sci USA 1993; 90:8683-8686.
68. Moodie SA, Willumsen BM, Weber MJ, Wolfman A. Complexes of Ras GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 1993; 260:1658-1661.
69. Kikuchi A, Williams LT. The post-translational modification of ras p21 is important for Raf-1 activation. J Biol Chem 1994; 269:20054-20059.
70. Levitzki A. Signal transduction therapy: a novel approach to disease management. Eur J Biochem 1994; 226:1-13.
71. Crespo P, Xu N, Simonds WF, Gutkind JS. Ras-dependent activation of MAP kinase pathway mediated by G protein by subunits. Nature 1994; 369:418-420.
72. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995; 80:179-185.
73. Denhardt DT. Signal-transduction protein phos-phorylation cascade mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signaling. Biochem J 1996; 318:729-747.
74. Salmeron A, Ahmad TB, Carlile GW, Pappin D, Narsimhan RP, Ley SC. Activation of MEK-1 and SEK-1 by Tpl-2 protooncoprotein, a novel MAP kinase kinase. EMBO J 1996; 15:817-826.
75. Mansour SJ, Matten WT, Hermann AS. Transformation of mammalian cells by constitutive active MAP kinase kinase kinase. Science 1994; 265:966-970.
76. Patriotis C, Makris A, Chemoff J, Tsichlis PN. Tpl-2 acts in concrete with Ras and Raf-1 to activate mitogen-activated protein kinase. Proc Natl Acad Sci USA 1994; 91:9755-9759.
77. Keys A, Aravanis C, Blackburn H, Buzina R, Dontos AS, Fidanza F, Karuonen MJ, Menotti A, Nedilijkovic S, Punsar S. Serum cholesterol and cancer mortality in the seven countries study. Am J Epidemiol 1985; 121:870-883.
78. Hiatt RA, Fireman BH. Serum cholesterol and the influence of cancer in a large cohort. J Chronic Dis 1986; 39:861-870.
79. Sherwin RW, Wentworth DN, Cutler JA, Hulley SB, Kuller LH, Stamler J. Serum cholesterol levels and cancer mortality in 361,662 men for the multiple risk factor intervention trial. JAMA 1987; 257:943-948.
80. Knekt P, Peunanen A, Aromaa A, Heliovaara M, Hakulinen T, Hakama M. Serum cholesterol and risk of cancer in a cohort of 39,000 men and women. J Clin Epidemiol 1988; 41:519-530.
81. Schatzkin A, Hoover RN, Taylore PR, Zeigler RG, Carter CL, Albanes, D, Larson DB, Licitra LM. Site-specific analysis of total serum cholesterol and incident cancer in the National Health and Nutrition Examination Survey. I. Epidemiologic follow-up study. Cancer Res 1988; 48:452-458.
82. Bobek P, Galbavy S, Mariassyova M. The effect of red beet (Beta vulgaris Var rubra) fiber on alimentary hypercholesterolemia and chemically induced colon carcinogenesis in rats. Nahrung 2000; 44:184-187.
83. Pussinen PJ, Karten B, Wintersperger A, Reicher H, McLean M, Malle E, Sattler W. The human breast carcinoma cell line BHL-100 acquires exogenous cholesterol from high-density lipoprotein via CLA-1 (CD-36 and LIMPII analogous-1) mediated selective cholesterol ester uptake. Biochemistry 2000; 349:559-566.
84. Miettinen TA, Gylling H, Lindbohm N, Miettinen TE, Rajaratnam RA, Relas H. Serum non-cholesterol sterols during inhibitions of cholesterol synthesis by statins. J Lab Clin Med 2003; 141(2):131-137.
85. Coleman PS. Deterministic coupling between cellular biogenesis, cholesterol synthesis, cell proliferation and cancer. In: Columbano A, Feo F, Pascale R, Pani P, editors. Chemical Carcinogenesis 2. New York: Plenum, 1991.
86. Coleman PS, Lavietes B, Born R, Weg A. Cholesterol enrichment of normal mitochondria in vitro: a model system with properties of hepatoma mitochondria. Biochem Biophys Res Commun 1978; 84:202-207.
87. Kromhout D, Bossechieter EB, Breijver M, de Lenenne CC. Serum cholesterol and 25-year incidence of mortality from myocardial infraction and cancer: the Zuphen study. Arch Intern Med 1988; 148:1051-1055.
88. Edwards PA, Lan SF, Fogelman AM. High-density lipoproteins and lecithin dispersions increase the activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase by increasing the rate of synthesis and decreasing the rate of degradation of the enzyme. J Biol Chem 1984; 259:8159-8194.
89. Coleman PS, Chen LC, Sepp-Lorenzino L. Cholesterol metabolism and tumor cell proliferation. In: Bittman R, editor. Subcellular Biochemistry. New York: Plenum, 1997.
90. Quesney-Huneeus V, Galick HA, Siperstein MP, Erickson SK, Spencer TA, Helson JA. The dual role of mavelonate in the cell cycle. J Biol Chem 1983; 258:378-385.
91. Doyle J, Kabakoff B, Kandutsch AA. Dolicyl-phosphate as a regulator of cell growth. In: Columbano A, Feo F, Pascale R, Pani P, editors. Chemical Carcinogenesis 2. New York: Plenum, 1991.
92. Kiguchi K, Kagehara M, Higo R, Iwameri M, Di Giovanni J. Alternations in cholesterol sulfate and its biosynthetic enzyme during multistage carcinogenesis in mouse skin. J Invest Dermatol 1998; 111 (6):973-981.
93. Kuroki T, Ikuta T, Mashiwagi M, Kawabe S, Ohba M, Huh N, Mizuno, K Ohno S, Yamada E, Chida K. Cholesterol sulfate, an activator of protein kinases C mediating squamous cell differentiation: a review. Mutat Res 2000; 462:189-195.
94. Barbacid M. Ras genes. Annu Rev Biochem 1987; 56:779-827.
95. Shack S, Gorospe SM, Fawcett TW, Hudgins WR, Holbrook NJ. Activation of the cholesterol pathway and ras maturation in response to stress. Oncogene 1999; 28:6021-6028.
96. Smith IJ, Squalene. Potential chemopreventive agent. Expert Opin Invest Drug 2000; 9(8):1841-1848.
97. El-Sohemy A, Archer MC. Inhibition of N-methyl-N-nitrosourea and 7,12-dimethylbenz[a] anthracene-induced rat mammary tumorigenesis by dietary cholesterol is independent of Ha-Ras mutations. Carcinogenesis 2000; 21:827-831.
98. Perraiz S. Anti-cancer drugs of today and tomorrow: are we close to making the turn from treating to curing cancer? Curr Pharm Des 2002; 8(19):1723-1734.
99. Lenz M, Miehe WP, Vanrenwald F, Bruchelt G, Schweizer P, Girgert R. Cholesterol based antineoplastic stratergies. Anticancer Res 1997, 17(2A):1143-1146.
100. Bos JL. Ras oncogenes in human cancer. Cell 1989; 64:235-248.
101. Midgley RS, Kerr DJ. Ras as a target in cancer therapy. Crit Rev Oncol Hematol 2002; 2:109-120.
102. Buss JE, Marsters JC Jr. Farnesyl transferase inhibitors: the successes and surprises of a new class of potential cancer chemotherapeutics. Chem Biol 1995; 2:787-791.
103. Gibbs JB, Oliff A. The potential of farnesyl transferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmocol Toxicol 1997; 37:143-166.
104. Kim, Y, Lim S, Park K, Na K. Correlation of K-ras mutation and K-ras protein expression in non-small cell lung cancer. Lung Cancer 2002; 29(1):206.
105. Warne PH, Rodriguez VP, Downward J. Direct interaction of Ras and amino-terminal domain of Raf-1 in vitro. Nature 1993; 364:352-355.
106. Spaargaren M, Bischoff JR, McCormick F. Signal transduction by Ras-like GTPases: a potential target for anticancer drug. Gene Exp 1995; 4:345-356.
107. Haluska P, Dy GK, Adjei AA. Farnesyl transferase inhibitors as anticancer agents. Eur J Cancer 2002; 38(13):1685-1700.
108. Johnston SR. Farnesyl transferase inhibitors: a novel targeted therapy for cancer. Lancet Oncol 2001; 2(1):18-26.
109. Hara M, Akasaka K, Akinaga S, Okabe M, Nakano H, Gomez R, Wood D, Uh M, Tamanoi F. Identification of ras farnesyltransferase inhibitors by microbial screening. Proc Natl Acad Sci USA 1993; 90:2281-2285.
110. Nigam M, Seong CM, Qian Y, Hamilton AD, Sebti SM. Potent inhibition of human tumor p21 ras farnesyl transferase by A1A2-lacking p21 ras CA1CA2X peptidomimetics. J Biol Chem 1993; 268:20695-20698.
111. Qian Y, Blaskovich MA, Saleem M, Seong M, Wathen SP, Hamilton AD, Sebti SM. Design and structural requirement of potent peptidominetic inhibitors of p21 ras farnesyltransferase. J Biol Chem 1994; 269:12410-12413.
112. Bellosta S, Paoletti R, Corsini A. History and development of HMG-CoA reductase inhibitors. Milestones in Drug Therapy. Basel: Birkhauser Verlag, 2002.
113. Crowell PL, Gould MN. Chemoprevention and therapy of cancer by d-limonene. Crit Rev Oncog 1994; 5:1-22.
114. Pearce BC, Parker RA, Deasen ME, Qureshi AA, Wright JJ. Hypocholesterolemic activity of synthetic and natural tocotrienols. J Med Chem 1992; 35:3595-3606.
115. Parker RA, Pearce BC, Clark RW, Gorden DA, Wright JJ. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3 methylglutaryl-coenzyme A reductase. J Biol Chem 1993; 268:11230-11238.
116. Bradfute DL, Simoni RD. Non-sterol compounds that regulate cholesterogenesis: analogues of farnesyl pyrophosphate reduce 3-hydroxy-3-methylglutaryl-co-enzyme A reductase levels. J Biol Chem 1994; 269:6645-6650.